Abstract
Aims: Combine prospective report of cannabis use with retrospective report of potency to infer the potency of cannabis used in adolescence and explore whether use of cannabis, and the use of high-potency cannabis, in adolescence is associated with incident psychotic experiences.
Design: Population-based birth cohort study.
Setting: United Kingdom
Participants: N=5570 participants who reported on any cannabis use (yes/no) age 16 and 18 years, and N=1560 participants from this group who also retrospectively reported on cannabis potency.
Measurements: In questionnaires at ages 16 and 18 individuals self-reported lifetime cannabis use, and at age 24, participants reported the type of cannabis they most commonly used in the whole time since first using cannabis. Psychotic experiences were assessed at age 24 years using the semi-structured Psychosis-Like Symptom Interview, with incident defined as new-onset occurring between ages 19 and 24 years.
Findings: Results indicated use of high-potency cannabis at age 16 or 18 is associated with twice the likelihood of experiencing incident psychotic experiences from age 19-24 (Odds Ratio 2.15, 95% Confidence Intervals 1.13-4.06). There was less evidence for an effect of any cannabis use on incident psychotic experiences (Odds Ratio 1.45, 95% Confidence Intervals 0.94 - 2.12).
Conclusions: This work contributes to a growing body of evidence indicating that use of high-potency cannabis is associated with increased likelihood of psychotic experiences.
Original language | English |
---|---|
Pages (from-to) | 1629-1634 |
Number of pages | 6 |
Journal | Addiction |
Volume | 119 |
Issue number | 9 |
Early online date | 13 May 2024 |
DOIs | |
Publication status | Published - 30 Sept 2024 |
Data Availability Statement
The informed consent obtained from ALSPAC participants does not allow for the data to be made freely available through any third party maintained public repository. However, data used for this Article can be made available on request to the ALSPAC Executive. The ALSPAC data management plan describes in detail the policy regarding data sharing, which is through a system of managed open access. Full instructions for applying for data access can be found here: http://www.bristol.ac.uk/alspac/researchers/access/. The ALSPAC study website contains details of all the data that are available (http://www.bristol.ac.uk/alspac/researchers/our-data/).Funding
LAH is funded by the Wellcome Trust (Grant ref: 209158/Z/17/Z). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. SZ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The work was undertaken with the support of the MRC (MR/M006727/1) and the MRC and Alcohol Research UK (MR/L022206/1). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.
Funders | Funder number |
---|---|
National Institute for Health and Care Research Biomedical Research Centre at University Hospitals Bristol and Weston National Health Service | |
Niilo Helanderin Säätiö | |
Newcastle upon Tyne Hospitals NHS Foundation Trust | |
University of Bristol | |
Wellcome Trust | 209158/Z/17/Z |
Medical Research Council | MR/M006727/1 |
Alcohol Research United Kingdom | MR/L022206/1 |
Keywords
- Humans
- Adolescent
- Male
- Female
- Self Report
- Young Adult
- United Kingdom/epidemiology
- Longitudinal Studies
- Psychoses, Substance-Induced/epidemiology
- Cannabis
- Psychotic Disorders/epidemiology
- Marijuana Use/epidemiology
- Risk Factors
- Prospective Studies
- Cohort Studies
- Marijuana Smoking/epidemiology
- Surveys and Questionnaires
- Retrospective Studies
ASJC Scopus subject areas
- Psychiatry and Mental health
- Medicine (miscellaneous)